This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More
by Zacks Equity Research
Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
Thermo Fisher (TMO) Extends Collaboration With Moderna
by Zacks Equity Research
Thermo Fisher (TMO) continues to be a trusted partner of Moderna, bringing a wide range of products and services enabling Moderna to deliver innovative medicines at an extraordinary speed and scale.
Moderna (MRNA) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.
Moderna (MRNA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Intriguing Earnings Charts
by Tracey Ryniec
Will these 5 companies break out, or break down, after they report earnings this week?
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
by Zacks Equity Research
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
Endo (ENDP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endo's (ENDP) fourth-quarter earnings might have gained from higher sales of Xiaflex.
Geopolitical Fear From Russia's Ukrainian-Advance Drive Stocks Lower
by Daniel Laboe
The US's economic growth outlook, inflationary issues, and uncertain monetary policy are far more important than anything happening in Eastern Europe when assessing the stock market from a macro perspective
What to Expect From Precision BioSciences (DTIL) Q4 Earnings
by Zacks Equity Research
On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.
Universal Health (UHS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Universal Health Services' (UHS) fourth-quarter results are likely to reflect the benefits of improving patient volumes.
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.
Allakos (ALLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Allakos' (ALLK) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's lead pipeline candidate, lirentelimab.
Moderna (MRNA) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $145.74 in the latest trading session, marking a -0.42% move from the prior day.
Moderna (MRNA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
Mednax (MD) to Post Q4 Earnings: Here's What You Need to Know
by Zacks Equity Research
Mednax's (MD) fourth-quarter results are likely to reflect growth in same-unit revenues and NICU days.
Stock Market News for Feb 15, 2022
by Zacks Equity Research
Wall Street lower on Monday as geopolitical tensions between Russia and Ukraine intensified.
Will Patient Days Drive Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health Systems' (CYH) fourth-quarter results are likely to reflect a higher occupancy rate and average length of stay.
Pfizer (PFE) Plans to Delay Comirnaty for Kids EUA Submission
by Zacks Equity Research
Pfizer (PFE) and its partner BioNTech are planning to extend their rolling submission to the FDA for the authorization of Comirnaty for use in children 6 months through 4 years of age to include the three-dose data.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $161.32, marking a +0.56% move from the previous day.
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study
by Zacks Equity Research
CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.
Novavax's (NVAX) COVID Vaccine Achieves Study Goal in Kids
by Zacks Equity Research
Novavax's (NVAX) COVID vaccine achieves 80% overall efficacy in a phase III study in adolescents aged between 12 and 17.